Observational studyBMC cancer2019
Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer.
Observational study in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of stem-like circulating tumor cells in patients with cancer: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Prognostic Significance of Circulating Tumor Cells in Patients with Esophageal Cancer Who Attained Pathological Complete Response after Neoadjuvant Therapy.Journal of chest surgery · 2026Article
- CD133 Expression in Circulating Tumor Cells as a Prognostic Marker in Colorectal Cancer.International journal of molecular sciences · 2025Article
- Nanobiotechnology augmented cancer stem cell guided management of cancer: liquid-biopsy, imaging, and treatment.Journal of nanobiotechnology · 2024Review
- Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapy.NPJ breast cancer · 2023Article
- Circulating tumor cells (CTCs) and hTERT gene expression in CTCs for radiotherapy effect with lung cancer.BMC cancer · 2023Article
- An Image-Based Identification of Aggressive Breast Cancer Circulating Tumor Cell Subtypes.Cancers · 2023Article
- Exploring the Role of Hypoxia-Inducible Carbonic Anhydrase IX (CAIX) in Circulating Tumor Cells (CTCs) of Breast Cancer.Biomedicines · 2023Article
- Sulforaphane: An emergent anti-cancer stem cell agent.Frontiers in oncology · 2023Review
- Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer.International journal of molecular sciences · 2022Review
- Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer.Therapeutic advances in medical oncology · 2022Article
- Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors.Scientific reports · 2021Article
- Enhancing Prediction Performance by Add-On Combining Circulating Tumor Cell Count, CD45Cancers · 2021Article
- Lymph Liquid Biopsy for Detection of Cancer Stem Cells.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2021Article
- Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.International journal of molecular sciences · 2021Review
- Review
- Circulating Tumor Cells: A Promising Biomarker in the Management of Nasopharyngeal Carcinoma.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundCirculating tumor cells (CTCs) are associated with breast cancer prognosis. Research is limited regarding the role of circulating cancer stem-like cells (cCSCs) considering the treatment response and survival among patients with metastatic breast cancer. Accordingly, we performed this prospective study to clarify the prognostic significance of baseline cCSCs for metastatic breast cancer in terms of first-line chemotherapy.
methodsBetween April 2014 and January 2016, we prospectively enrolled 48 patients with stage IV breast invasive ductal carcinoma who underwent first-line chemotherapy. We identified and analyzed CTCs and cCSCs by using a protocol based on negative selection and flow cytometry before chemotherapy. CTCs were identified as EpCAM
resultsWe identified CTCs in all the enrolled patients, with a median number of 33.9/mL CTCs. CSCs were isolated in 97.9% of the patients; the median percentage of cCSCs was 14.7%. A high baseline level of cCSCs was correlated with an inferior tumor response rate (54.2% vs. 95.8%, p < 0.001), overall survival (OS; median: 27.7 months vs. not reached, p < 0.001), and progression-free survival (PFS; median: 5.7 vs. 18.0 months, p < 0.001). Multivariate analysis revealed that along with other clinical variables, baseline cCSCs remained an independent prognostic factor for OS and PFS.
conclusionsBaseline cCSCs predict the treatment response as well as survival in patients with metastatic breast cancer undergoing first-line chemotherapy. Therefore, the measurement of cCSCs may assist in identifying early cancer treatment response and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.